Advertisement

Haare pp 499-570 | Cite as

Allgemeine Therapie von Haarkrankheiten

  • Ralph M. Trüeb
Chapter
  • 210 Downloads

Zusammenfassung

Haarwuchsprobleme sind häufig, Betroffene zeigen einen oft hohen Leidensdruck, und die Behandlungsmöglichkeiten sind beschränkt. Vor diesem Hintergrund hat die Bewältigung von Haarproblemen auf den Ebenen des Informationsverhaltens, der Problemlösekompetenz und der medizinischen Therapie zu erfolgen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Fey MF, Bührer A (2001) Klinische Fachliteratur kritisch lesen. Teil I: Fussangeln in Fallberichten und Fallserien. Schweiz Med Forum 7:161–165Google Scholar
  2. Fey MF, Bührer A (2001) Klinische Fachliteratur kritisch lesen. Teil II: Randomisierte Studien, Meta-Analysen und Publikationsprobleme. Schweiz Med Forum 7:166–171Google Scholar
  3. Grilli R, Freemantle N, Minozzi S et al. (1999) Einfluss von Massenmedien auf die Inanspruchnahme medizinischer Leistungen. Schweiz Rundsch Med Prax 88:1839Google Scholar
  4. Lange S (2000) Statistische Signifikanz und klinische Relevanz. Zeitschr Hautkrankh 4:225–229Google Scholar
  5. Trüeb RM, Schweizerische Arbeitsgruppe für Trichologie (2000) Die Wechselbeziehung zwischen Arzt, Friseur und Medien im Management von Haarverlust. Hautarzt 51:729–732PubMedCrossRefGoogle Scholar
  6. Trüeb RM, de Viragh P, Schweizerische Arbeitsgruppe für Trichologie (2001) Stellenwert der Kopfhaare und Therapie von Haarausfall bei Männern in der Schweiz. Schweiz Rundsch Med Prax 90:241–248Google Scholar
  7. Trüeb RM, Itin P, Schweizerische Arbeitsgruppe für Trichologie (2001) Fotografische Dokumentation der Wirksamkeit von 1 mg oralem Finasterid in der Behandlung der androgenetischen Alopezie des Mannes im Praxisalltag in der Schweiz. Schweiz Rundsch Med Prax 90:2087–2093Google Scholar

■ Literatur

  1. Ackerman AB, Kligman AM (1969) Some observations on dandruff. J Soc Cosm Chem 20:81–101Google Scholar
  2. Adams RM, Maibach HI (1985) A five-year study of cosmetic reactions. J Am Acad Dermatol 13:1062–1069PubMedCrossRefGoogle Scholar
  3. Bouillon C (1996) Shampoos. Clin Dermatol 14:113–121PubMedCrossRefGoogle Scholar
  4. Christophers E (1995) Mehr Nutzen als Risiken durch Teershampoos. Polyzyklische aromatische Kohlenwasserstoffe in der Diskussion. Forsch Prax 201: 28–30Google Scholar
  5. Dawber R (1996) Hair: Its structure and response to cosmetic preparations. Clin Dermatol 14:105–112PubMedCrossRefGoogle Scholar
  6. Dawber R (1996) Shampoos — scientific basis and clinical aspects. International Congress and Symposium Series 216. The Royal Society of Medicine Press Limited, LondonGoogle Scholar
  7. Domsch A, Pospischil H, Schuster G, Tronnier H (1996) Kosmetisch-dermatologische Wirkungen von Eiweisshydrolysaten. Parfüm Kosmet 61:325–330Google Scholar
  8. Fewings J, Menné T (1999) An update of the risk assessment for methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) with focus on rinse-off products. Contact Dermatitis 41:1–13PubMedCrossRefGoogle Scholar
  9. Fransway AF (1991) The problem of preservation in the 1990s: I. Statement of the problem, solution(s) of the industry, and the current use of formaldehyde and formaldehyde-releasing biocides. Am J Contact Derm 2:6–23Google Scholar
  10. Futterer E (1988) Antidandruff hair tonic containing piroctone olamine. Cosmet Toiletries 103:49–52Google Scholar
  11. Kullavanijaya P, Gritiyarangsan P, Bisalbutra P et al. (1992) Absence of effects of dimethicone-and non-dimethicone-containing shampoos on daily hair loss rates. J Soc Cosm Chem 43:195–206Google Scholar
  12. Merk HF, Mukhtar H, Kaufmann I et al. (1987) Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolisme: effect of exposure to a coal tar containing shampoo. J Invest Dermatol 88:71–76PubMedCrossRefGoogle Scholar
  13. Merk H, Loew D, Lorke D (1990) Topische Anwendung des Steinkohlenteers: Nutzen-Risiko-Abwägung aus klinischer, pharmakologischer und toxikologischer Sicht. Akt Dermatol 16:147–151Google Scholar
  14. Pittelkow MR, Perry HO, Muller SA et al. (1980) Skin cancer in patients with psoriasis treated with coal tar. Arch Dermatol 117:465–468CrossRefGoogle Scholar
  15. Price NCP (1995) 50 years of surfactants cosmetic cleansing and emulsions. Cosmet Toiletries 110:49–66Google Scholar
  16. Reng AK (1977) Rezeptierung von Haarreinigungsund-nachbehandlungspräparaten mit speziellen Eigenschaften.SÖFW 8/9/11:1–9Google Scholar
  17. Rushton H, Gummer CL, Flasch H (1994) 2-in-1 shampoo technology: state of the art shampoo and conditioner in one. Skin Pharmacol 7:78–83PubMedCrossRefGoogle Scholar
  18. Shapiro J, Maddin S (1996) Medicated shampoos. Clin Dermatol 14:123–128PubMedCrossRefGoogle Scholar
  19. Spoor HJ (1973) Shampoos. Cutis 12:167–168Google Scholar
  20. Spoor HJ (1977) Shampoos and hair dyes. Cutis 20: 189–190PubMedGoogle Scholar
  21. Sugimura T, Sato S, Nagao M et al. (1976) Overlapping of carcinogens and mutagens. In: Magee, Takayana, Sugimura, Matsushima (eds) Fundamentals in Cancer Prevention. University of Tokyo Press, Tokyo, p 191Google Scholar
  22. Swisher RD (1987) Surfactant Biodegradation. Marcel Dekker, New YorkGoogle Scholar
  23. Trüeb RM (1998) Haarwaschmittel (Shampoos): Zusammensetzung und klinische Anwendungen. Hautarzt 49:895–901PubMedCrossRefGoogle Scholar
  24. Urbano CC (1995) 50 years of hair care development. Cosmet Toiletries 110:85–104Google Scholar
  25. Van Schooten FJ, Moonen EJ, Rhynsburger E et al. (1994) Dermal uptake of polycyclic aromatic hydrocarbons after hair wash with coal tar shampoo. Lancet 344:1505–1506PubMedCrossRefGoogle Scholar
  26. Zviak C, Bouillon C (1986) Hair treatment and hair care products. In: Zviak C (ed) The Science of Hair Care. Marcel Dekker, New York, pp 87–147Google Scholar
  27. Zviak C, Vanlerberghe G (1986) Scalp and hair hygiene. In: Zviak C (ed) The Science of Hair Care. Marcel Dekker, New York, pp 49–86Google Scholar

■ Literatur

  1. Brenner S, Matz H (1999) Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. Int J Dermatol 38:926–930CrossRefGoogle Scholar
  2. Castro-Maganoa M, Angulo M, Fuentes B et al. (1996) Effect of finasteride on human testicular steroidgenesis. J Androl 17:516–521Google Scholar
  3. Chen W, Zouboulis ChC, Orfanos CE (1996) The 5-alpha reductase system and its inhibitors. Recent developments and its perspectives in treating androgen-dependent skin disorders. Dermatol 193:177–184CrossRefGoogle Scholar
  4. Dallob AL, Sadick NS, Unger W et al. (1994) The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 79:703–706PubMedCrossRefGoogle Scholar
  5. Gormley GJ, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185–1191PubMedCrossRefGoogle Scholar
  6. Gormley GJ (1995) Finasteride: a clinical review. Biomed Pharmacother 49:319–324PubMedCrossRefGoogle Scholar
  7. Harris GS, Kozarich JW (1997) Steroid 5alpha-reductase inhibitors in androgen-dependent disorders. Curr Opin Chem Biol 1:254–259PubMedCrossRefGoogle Scholar
  8. Kaufman KD (1996) Clinical studies on the effects of oral finasteride, a type II 5α-reductase inhibitor, on scalp hair in men with male pattern baldness. In: van Neste D, Randall VA (eds) Hair Research for the Next Millenium. Elsevier, Amsterdam, pp 363–365Google Scholar
  9. Kaufman KD, Olsen EA, Whiting D et al. (1998) Finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Am Acad Dermatol 36:578–589CrossRefGoogle Scholar
  10. Leyden J, Dunlap F, Miller B et al. (1999) Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 40:930–937PubMedCrossRefGoogle Scholar
  11. Mazzarella F, Loconsole F, Cammisa A et al. (1997) Topical finasteride in the treatment of androgenic alopecia. J Dermatol Treatment 8:189–192CrossRefGoogle Scholar
  12. Navarro Guerrero J, Lorduy Oses L. Galenic-pharmaceutical study of pieces of Proscar® (finasteride 5 mg) tablets and finasteride 1 mg capsules versus Propecia® in the treatment of androgenetic alopecia (im Druck)Google Scholar
  13. Overstreet JW, Fuh VL, Gould J et al. (1999) Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 162:1295–1300PubMedCrossRefGoogle Scholar
  14. Price VH, Roberts JL, Hordinsky M et al. (2000) Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 43:768–776PubMedCrossRefGoogle Scholar
  15. Rittmaster RS (1994) Finasteride. N Engl J Med 330: 120–125PubMedCrossRefGoogle Scholar
  16. Sudduth SL, Koronkowski MJ (1993) Finasteride: the first 5 alpa-reductase inhibitor. Pharmacotherapy 13:309–325PubMedGoogle Scholar
  17. Trüeb RM, Itin P und Schweizerische Arbeitsgruppe für Trichologie (2002) Fotografische Dokumentation der Wirksamkeit von 1 mg oralem Finasterid in der Behandlung der androgenetischen Alopezie des Mannes im Praxisalltag. Schweiz Rundsch Med Prax 90:2087–2093Google Scholar
  18. Van Neste D, Fuh V, Sanchez-Pedreno P et al. (2000) Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 143:804–810PubMedCrossRefGoogle Scholar
  19. Wolff H, Kunte C (1998) Die Behandlung der androgenetischen Alopezie des Mannes mittels systemischer 5-Reduktase-Hemmung. Hautarzt 49:813–817PubMedCrossRefGoogle Scholar

■ Literatur

  1. Moltz L, Schwartz U, Hammerstein J (1980) Die klinische Anwendung von Antiandrogenen bei der Frau. Gynäkologe 13:1–17PubMedGoogle Scholar
  2. Sawaya ME, Hordinsky MK (1993) The antiandrogens. When and how they should be used. Dermatol Clin 11:65–72PubMedGoogle Scholar

■ Literatur

  1. Buhl AE, Waldon DJ, Kawabe TT, Holland JM (1989) Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 92:315–320PubMedCrossRefGoogle Scholar
  2. Buhl AE (1991) Minoxidil’s action in hair follicles. J Invest Dermatol 96(Suppl):73S–74SPubMedCrossRefGoogle Scholar
  3. Civatte J, Laux B, Simpson NB, Vickers CFH (1987) 2% topical minoxidil solution in male pattern baldness: preliminary European results. Dermatologica 175(Suppl):42–49PubMedCrossRefGoogle Scholar
  4. De Groot AC, Nater JP, Herxheimer A (1987) Minoxidil: hope for the bald? Lancet 1:1019–1022PubMedCrossRefGoogle Scholar
  5. De Villez RL (1990) The therapeutic use of topical minoxidil. Dermatol Clin 8:367–375Google Scholar
  6. De Villez RL, Jacobs JP, Szpunar CA, Varner ML (1994) Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol 3:303–307Google Scholar
  7. Ebner H, Müller E (1995) Allergic contact dermatitis from minoxidil. Contact Dermatitis 32:316–317PubMedCrossRefGoogle Scholar
  8. Headington JT, Novak E (1984) Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res 36:1098–1106Google Scholar
  9. Katz HI, Hien NT, Prawer SE, Goldman SJ (1987) Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol 16:711–718PubMedCrossRefGoogle Scholar
  10. Katz HI (1988) Topical minoxidil: review of efficacy. Clin Dermatol 6:195–199PubMedCrossRefGoogle Scholar
  11. Katz HI (1989) Topical minoxidil: review of efficacy and safety. Cutis 43:94–98PubMedGoogle Scholar
  12. Kreindler TG (1987) Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol 16:718–724PubMedCrossRefGoogle Scholar
  13. Kubilus J, Kvedar JC, Baden HP (1987) Effect of minoxidil on pre-and postconfluent keratinocytes. J Am Acad Dermatol 16:648–652PubMedCrossRefGoogle Scholar
  14. Olsen EA (1989) Treatment of androgenetic alopecia with topical minoxidil. Res Staff Phys 35:53–69Google Scholar
  15. Olsen EA, Weiner MS, Amara IA, DeLong ER (1990) Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 22:643–646PubMedCrossRefGoogle Scholar
  16. Price VH, Menefee E (1990) Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 95:683–687PubMedCrossRefGoogle Scholar
  17. Price VH, Menefee E, Strauss PC (1999) Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 41:717–721PubMedCrossRefGoogle Scholar
  18. Rietschel RL, Duncan SH (1987) Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 16:677–685PubMedCrossRefGoogle Scholar
  19. Savin RC, Atton AV (1993) Minoxidil. Update on its clinical role. Dermatol Clin 11:55–64PubMedGoogle Scholar
  20. Scheman AJ, West DP, Hordinsky MK et al. (2000) Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients. Contact Dermatitis 42:241PubMedGoogle Scholar
  21. Tosti A, Bardazzi F, De Padova MO et al. (1985) Contact dermatitis to minoxidil. Contact Dermatitis 13:275–276PubMedCrossRefGoogle Scholar
  22. Van der Willligen AH, Dutree-Meulenberg ROGM, Stolz E et al. (1987) Topical minoxidil sensitization in androgenic alopecia. Contact Dermatitis 17:44–45CrossRefGoogle Scholar
  23. Whiting DA, Jacobson C (1992) Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol 31:800–804PubMedCrossRefGoogle Scholar
  24. Whitmore EX (1992) The importance of proper vehicle selection in the detection of minoxidil sensitivity. Arch Dermatol 128:653–656PubMedCrossRefGoogle Scholar
  25. Wilson C, Walkden V, Powell S et al. (1991) Contact dermatitis in reaction to 2% topical minoxidil solution. J Am Acad Dermatol 24:661–662PubMedCrossRefGoogle Scholar
  26. Zins GR (1988) The history of the development of minoxidil. Clin Dermatol 6:132–147PubMedCrossRefGoogle Scholar

■ Literatur

  1. Enders HJ (1980) Zur Therapie von Haarausfall unterschiedlichster Genese mit einem östrogen-und kortikoidhaltigen Externum. Z Hautkr 55:14–18Google Scholar
  2. Gottswinter J (1984) Gynäkomastie durch östrogenhaltiges Haarwasser. Med Klein 79:181–183Google Scholar
  3. Hevert F (2000) 17α-Estradiol — ein moderner Inhibitor der 5α-Reductase. In: Plettenberg A, Meigel WN, Mill I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Berlin Heidelberg, S 435–437CrossRefGoogle Scholar
  4. Kiesewetter F, Schell H (2002) Wirksamkeit von 17α-Estradiol in der Therapie der Alopecia androgenetica (im Druck)Google Scholar
  5. Orfanos CE, Vogels L (1980) Lokaltherapie der Alopecia androgenetica mit 17-alpha-Östradiol. Dermatologica 161:124–132PubMedCrossRefGoogle Scholar
  6. Schumacher-Stock U, Winkler K (1977) Die externe Östrogentherapie der androgenetischen Alopezie. Hautarzt 11(Suppl):336–338Google Scholar
  7. Wozel G (2002) Lokaltherapie der androgenetischen Alopezie mit 17α-Estradiol bei Frauen und Männern (im Druck)Google Scholar
  8. Wüstner H, Orfanos CE (1974) Alopecia androgenetica und ihre Lokalbehandlung mit östrogen-und corticosteroidhaltigen Externa. Z Hautkr 49:879–888PubMedGoogle Scholar

■ Literatur

  1. Berth-Jones J, Burney AMC, Hutchinson PE (1994) Diphencyprone is not detectable in serum or urine following topical application. Acta Dermatol Venereol (Stockh) 74:312–313Google Scholar
  2. Cotellessa C, Peris K, Caracciolo E et al. (2001) The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 44:73–76PubMedCrossRefGoogle Scholar
  3. Gianetti A, Orecchia G (1983) Clinical experience on the treatment of alopecia areata with squaric acid dibutylester. Dermatologica 167:280–282CrossRefGoogle Scholar
  4. Gordon P, Aldridge G, McVittie E et al. (1996) Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow-up. Br J Dermatol 134:869–871PubMedCrossRefGoogle Scholar
  5. Happle R, Kalveran K, Buchner U et al. (1980) Contact allergy as therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 161:289–297PubMedCrossRefGoogle Scholar
  6. Hatzis J, Gourgiotou K, Tosca A (1988) Vitiligo as a reaction to topical treatment with diphencyprone. Dermatologica 177:146–148PubMedCrossRefGoogle Scholar
  7. Hoffmann R, Happle R (1996) Topical immunotherapy in alopecia areata: What, how, and why? Dermatol Clin 14:739–744PubMedCrossRefGoogle Scholar
  8. Micali G, Licastro-Cicero R, Nasca MR (1996) Treatment of alopecia areata with squaric acid dibutylester. Int J Dermatol 35:52–56PubMedCrossRefGoogle Scholar
  9. Monk B (1989) Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 14:154–157PubMedCrossRefGoogle Scholar
  10. Orrechia G, Rabbiosi G (1990) Treatment of alopecia areata with diphencyprone. Dermatologica 171: 193–196CrossRefGoogle Scholar
  11. Pericin M, Trüeb RM (1998) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology 196: 418–421PubMedCrossRefGoogle Scholar
  12. Perret CM, Steijlen PM, Zaun H, Happle R (1990) Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenonen. Dermatologica 180:5–7PubMedCrossRefGoogle Scholar
  13. Rokhsar CK, Shupack JL, Vafai JJ et al. (1990) Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 39:751–761CrossRefGoogle Scholar
  14. Shapiro J (1993) Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol Clin 11:611–617PubMedGoogle Scholar
  15. Tosti A, Guerra L, Bardazzi F (1989) Contact urticaria during topical immunotherapy. Contact Dermatitis 21:196–197PubMedCrossRefGoogle Scholar
  16. Tosti A, Guidetti MS, Bardazzi F et al. (1996) Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 35:199–201PubMedCrossRefGoogle Scholar
  17. Van der Steen P, van Baar H, Perret C (1991) Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 24:227–230PubMedCrossRefGoogle Scholar
  18. Van der Steen PHM, van Baar HMJ, Happle R et al. (1991) Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 24:227–230PubMedCrossRefGoogle Scholar
  19. Van der Steen P, Boezeman J, Happle R (1992) Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after additional follow-up period of 19 months. Dermatology 184:198–201PubMedCrossRefGoogle Scholar
  20. Van der Steen P, Happle R (1992) ‘Dyschromia in confetti’ as a side effect of topical immunotherapy with diphenylcyclopropenone. Arch Dermatol 128: 518–520PubMedCrossRefGoogle Scholar
  21. Weise K, Kretzschmar L, John SM et al. (1996) Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 192:129–133PubMedCrossRefGoogle Scholar
  22. Wilkerson MG, Henkin J, Wilkin JK (1984) Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol 11:802–807PubMedCrossRefGoogle Scholar
  23. Wilkerson MG, Henkin J, Wilkin JK (1985) Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 13:229–234PubMedCrossRefGoogle Scholar

■ Literatur

  1. Cornell RC, Stoughton RB (1987) Review of super-potent topical corticosteroids. Semin Dermatol 6:72–76Google Scholar
  2. DuVivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied steroids. Arch Dermatol 111:581–583PubMedCrossRefGoogle Scholar
  3. Firooz A, Tehranchi-Nia Z, Ahmed AR (1995) Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 20:363–370PubMedCrossRefGoogle Scholar
  4. Goldermann R, Teilkemeier P, Lehmann P et al. (1992) Typ-IV-Sensibilisierung gegen Kortikoide. Z Hautkr 67:430–435Google Scholar
  5. Lagos BR, Maibach HI (1998) Frequency of application of topical corticosteroids: an overview. Brit J Dermatol 139:763CrossRefGoogle Scholar
  6. Lester RS, Knowles SR, Shear NH (1998) The risks of systemic corticosteroid use. Dermatol Clin 16:277–288PubMedGoogle Scholar
  7. Mori M, Pimpinelli N, Giannotti B (1994) Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio. Drug Saf 10:406–412PubMedCrossRefGoogle Scholar
  8. Pflugshaupt C (1983) Diskontinuierliche topische Corticoidtherapie. Z Hautkr 148:1229–1238Google Scholar
  9. Reinhold U, Buttgereit F (2000) Hochdosis-Steroid-Pulstherapie. Gibt es Indikationen in der Dermatologie? Hautarzt 51:738–745PubMedCrossRefGoogle Scholar
  10. Smith EW (1995) Four decades of topical corticosteroid assessment. Curr Probi Dermatol 22:124–131Google Scholar
  11. Smith JG, Wahr RF, Chalker DK (1976) Corticosteroid induced atrophy and telangiectasia. Arch Dermatol 112:1115–1117PubMedCrossRefGoogle Scholar
  12. Staughton RCD, August PJ (1975) Cushing’s syndrome and pituitary-adrenal suppression due to clobetasol propionate. Br Med J 2:419–421PubMedCrossRefGoogle Scholar
  13. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM (1994) Severe adverse cardiovascular effects of pulse steroid therapy: is continuous monitoring necessary? J Am Acad Dermatol 30:768–773PubMedCrossRefGoogle Scholar
  14. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar

■ Literatur

  1. Anstey A (1995) Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 88:155–160Google Scholar
  2. Tan BB, Lear JT, Gawkrodger DJ et al. (1997) Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol 136:351–355PubMedCrossRefGoogle Scholar
  3. Younger IR, Harris DW, Colver GB (1991) Azathioprine in dermatology. J Am Acad Dermatol 25: 281–286PubMedCrossRefGoogle Scholar
  4. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar

■ Literatur

  1. Olsen EA (1991) The pharmacology of methotrexate. J Am Acad Dermatol 25:306–318PubMedCrossRefGoogle Scholar
  2. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD (1982) Methotrexate guidelines — revised. J Am Acad Dermatol 6:145–155PubMedCrossRefGoogle Scholar
  3. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar
  4. Zachariae H (1990) Methotrexate side-effects. Br J Dermatol 122(Suppl):127–133PubMedCrossRefGoogle Scholar

■ Literatur

  1. Ho VC, Gupta AK, Ellis CH et al. (1990) Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 22:64–68PubMedCrossRefGoogle Scholar
  2. Kahan BD (1989) Cyclosporine. N Engl J Med 321:1725–1738PubMedCrossRefGoogle Scholar
  3. Palestine AG, Nussenblatt RB, Chan C-C (1984) Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 77:652–658PubMedCrossRefGoogle Scholar
  4. Peter RU, Ruzicka T (1992) Cyclosporin A in der Therapie entzündlicher Dermatosen. Hautarzt 43:687–694PubMedGoogle Scholar
  5. Ruzicka T (1995) Cyclosporin in less common immune-mediated skin diseases. Br J Dermatol 48: 40–42Google Scholar
  6. Sönnichsen N (1993) Die Wirksamkeit von Ciclosporin bei Sonderformen der Psoriasis und nichtpsoriatischen Dermatosen. Dermatol Monatsschr 179: 163–168Google Scholar
  7. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar

■ Literatur

  1. Ochsendorf FR, Runne U (1991) Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika. Hautarzt 42:140–146PubMedGoogle Scholar
  2. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar

■ Literatur

  1. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar
  2. Wozel G (1996) Dapson. Pharmakologie, Wirkmechanismus und klinischer Einsatz. Georg Thieme, StuttgartGoogle Scholar

■ Literatur

  1. Dicken CH (1984) Retinoids: a review. J Am Acad Dermatol 11:541–552PubMedCrossRefGoogle Scholar
  2. Lesnik RH, Mezick JA, Capetola R, Kligman LH (1989) Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 21:186–190PubMedCrossRefGoogle Scholar
  3. McMichael AJ, Griffiths CE, Talwar HS et al. (1996) Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 135:60–64PubMedCrossRefGoogle Scholar
  4. Orfanos CE (1989) Retinoide: der neue Stand. Erhaltungstherapie, Resorptionsstörungen bei “non-responders”, Interaktionen und Interferenzen mit Medikamenten, Behandlung von Kindern und Knochentoxizität, Acitretin und 13-cis-Acitretin. Hautarzt 40:123–129PubMedGoogle Scholar
  5. Saurat J-H (1998) Systemic retinoids. What’s new? Dermatol Clin 16:331–340PubMedCrossRefGoogle Scholar
  6. Wolverton SE (1992) Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 26:661–679PubMedCrossRefGoogle Scholar

■ Literatur

  1. Barnes L, Altmeyer P, Forstrom L, Stentstrom MH (2000) Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 10:199–204PubMedGoogle Scholar
  2. Czarnetzki BM (1989) Vitamin D3 in Dermatology: a critical appraisal. Dermatologica 178:184–188PubMedCrossRefGoogle Scholar
  3. Duweb GA, Abuzariba O, Rahim M et al. (2000) Scalp psoriasis: topical calcipotriol 50 microgram/g/ml solution vs. Betamethasone 17-valerate 1% solution. Int J Clin Pharmacol Res 20:65–68PubMedGoogle Scholar
  4. Green C, Gampule M, Harris D et al. (1994) Comparative effects of calcipotriol (MC903) solution and placebo (vehicle MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 130:483–487PubMedCrossRefGoogle Scholar
  5. Klaber MR, Hutchinson PE, Pedvis-Leftick A et al. (1994) Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 131:678–683PubMedCrossRefGoogle Scholar
  6. Van de Kerkhof PCM, van Bokhoven M, Zultak M et al. (1989) A double-blind study of topical 1α,25-di-hydroxyvitamin D3 in psoriasis. Br J Dermatol 120:661–664PubMedCrossRefGoogle Scholar

■ Literatur

  1. Reimann S, Luger T, Metze D (2000) Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 51:164–172PubMedCrossRefGoogle Scholar

■ Literatur

  1. Abdel-Rahman SM, Nahata MC, Powell DA (1997) Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother 31:406–410PubMedGoogle Scholar
  2. Abdel-Rahman SM, Nahata MC (1997) Oral terbinafine: a new antifungal agent. Ann Pharmacother 31:445–456PubMedGoogle Scholar
  3. Abdel-Rahman SM, Powell DA, Nahata MC (1998) Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J Am Acad Dermatol 38:443–446PubMedCrossRefGoogle Scholar
  4. Albengres E, le Louet H, Tillement JP (1998) Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 18:83–97PubMedCrossRefGoogle Scholar
  5. Amichai B, Grunwald MH (1998) Adverse drug reactions of the new oral antifungals — terbinafine, fluconazole and itraconazole. Int J Dermatol 37:410–415PubMedCrossRefGoogle Scholar
  6. Bennett ML, Fleischer AB, Loveless JW, Feldman SR (2000) Oral griseofulvin remains the treatment of choice for tinea capitis in children. Pediat Dermatol17:304–309CrossRefGoogle Scholar
  7. De Beule K, van Gestel J (2001) Pharmacology of itraconazole. Drugs 61(Suppl):27–37PubMedCrossRefGoogle Scholar
  8. Dragos V, Lunder M (1997) Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediat Dermatol 14:46–48CrossRefGoogle Scholar
  9. Elewski BE (1999) Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol 40:27–30CrossRefGoogle Scholar
  10. Friedlander SF (1999) The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Pediat Infect Dis J 18:205–210CrossRefGoogle Scholar
  11. Goldman L (1970) Griseofulvin. Med Clin North Am 54:1339–1345PubMedGoogle Scholar
  12. Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview. Part I. J Am Acad Dermatol 30:677–698PubMedCrossRefGoogle Scholar
  13. Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview. Part II. J Am Acad Dermatol 30:911–933PubMedCrossRefGoogle Scholar
  14. Gupta AK, Shear NH (1997) Terbinafine: an update. J Am Acad Dermatol 37:979–988PubMedCrossRefGoogle Scholar
  15. Gupta AK, Alexis ME, Raboobee N et al. (1997) Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol 137:251–254PubMedCrossRefGoogle Scholar
  16. Gupta AK, Adam P, de Doncker P (1998) Itraconazole pulse therapy for tinea capitis: a novel treatment schedule. Pediat Dermatol 15:225–228CrossRefGoogle Scholar
  17. Gupta AK, Adam P (1998) Terbinafine pulse therapy is effective in tinea capitis. Pediat Dermatol 15:56–58CrossRefGoogle Scholar
  18. Gupta AK, Adam P, Soloman R, Aly R (1999) Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. Cutis 64:192–194PubMedGoogle Scholar
  19. Gupta AK, Katz HI, Shear NH (1999) Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 41:237–249PubMedCrossRefGoogle Scholar
  20. Gupta AK, Dlova N, Taborda P et al. (2000) Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 142:965–968PubMedCrossRefGoogle Scholar
  21. Haroon TS, Hussain I, Aman S et al. (1996) A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 135:86–88PubMedCrossRefGoogle Scholar
  22. Hoffman HL, Ernst EJ, Klepser ME (2000) Novel triazole antifungal agents. Expert Opin Invest Drugs 9:593–605CrossRefGoogle Scholar
  23. Jones TC (1995) Overview of the use of terbinafine (Lamisil®) in children. Br J Dermatol 132:683–689PubMedCrossRefGoogle Scholar
  24. Katz HI (1999) Drug interactions of the newer oral antifungal agents. Br J Dermatol 141(Suppl):26–32PubMedCrossRefGoogle Scholar
  25. Knasmuller S, Parzefall W, Helma C et al. (1997) Toxic effects of griseofulvin: disease models. Mechanisms, and risk assessment. Crit Rev Toxicol 27: 495–537PubMedCrossRefGoogle Scholar
  26. Korting HC, Schaller M (2001) Neue Entwicklungen in der medizinischen Mykologie. Hautarzt 52:91–97PubMedCrossRefGoogle Scholar
  27. Leyden J (1998) Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 38:42–47CrossRefGoogle Scholar
  28. Lopez-Gomez S, del Palacia A, van Custem J et al. (1994) Itraconazole versus griseofulvin in the treatment of tinea capitis: a double blind randomized study in children. Int J Dermatol 33:743–747PubMedCrossRefGoogle Scholar
  29. Moossavi M, Bagheri B, Scher RK (2001) Systemic antifungal therapy. Dermatol Clin 19:35–52PubMedCrossRefGoogle Scholar
  30. Montero GF (1998) Fluconazole in the treatment of tinea capitis. Int J Dermatol 37:870–871CrossRefGoogle Scholar
  31. Nejjam F, Zagula M, Carbiac MD et al. (1995) Pilot study of terbinafine in children suffering from tinea capitis: evalution of efficacy, safety, and pharmacokinetics. Br J Dermatol 132:98–105PubMedCrossRefGoogle Scholar
  32. Pierard GE, Arrese JE, Pierard-Franchimont C (2000) Itraconazole. Expert Opin Pharmacother 1:287–304PubMedCrossRefGoogle Scholar
  33. Rand S (2000) Overview. The treatment of dermatophytosis. J Am Acad Dermatol 43(Suppl):S104–S112PubMedCrossRefGoogle Scholar
  34. Smith EB (2000) The treatment of dermatophytosis: safety considerations. J Am Acad Dermatol 43(Suppl5):S113–S119PubMedCrossRefGoogle Scholar
  35. Solomon BA, Collins R, Sharma R et al. (1997) Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 37:274–275PubMedCrossRefGoogle Scholar
  36. Stevens DA (1999) Itraconazole in cyclodectrin solution. Pharmacotherapy 19:603–611PubMedCrossRefGoogle Scholar
  37. Suarez S, Friedlander SF (1998) Antifungal therapy in children: an update. Pediat Ann 27:177–184Google Scholar

■ Literatur

  1. Abeck D, Korting HC (1991) Einsatz von Antibiotika bei Hauterkrankungen. Bayer Internist 2:45–53Google Scholar
  2. Feingold DS, Wagner RF (1989) Antibacterial therapy. J Am Acad Dermatol 14:535–548CrossRefGoogle Scholar

■ Literatur

  1. Arndt KA (1988) Adverse reactions to acyclovir: topical, oral and intravenous. J Am Acad Dermatol 18:188–190PubMedCrossRefGoogle Scholar
  2. Evans TY, Tyring SK (1998) Advances in antiviral therapy in dermatology. Dermatol Clin 16:409–420PubMedGoogle Scholar

■ Literatur

  1. Eggensperger H (1980) Wirkstoffe zur Hautdesinfektion. Dtsch Apoth Ztg 120:28–30Google Scholar
  2. Kwochka K, Kowalski J (1991) Prophylactic efficacy of four antibacterial shampoos against Staphylococcus intermedius in dogs. Am J Vet Res 52:115–118PubMedGoogle Scholar
  3. Michael J (1977) Klinische Erfahrungen mit Betaisadona-Mikrobiziden in Chirurgie und Orthopädie. Therapiewoche 27:9328–9330Google Scholar
  4. Sebben JE (1983) Surgical antiseptics. J Am Acad Dermatol 9:759–765PubMedCrossRefGoogle Scholar
  5. Torricelli R, Wüthrich B (1996) Life-threatening anaphylactic shock due to skin application of chlorhexidine. Clin Exp Dermatol 26:112Google Scholar

■ Literatur

  1. Bowerman J, Gomez M, Austin R, Wold D (1987) Comparative study of permethrin 1% creme rinse and lindane shampoo for the treatment of head lice. Pediat Infect Dis J 6:252–255CrossRefGoogle Scholar
  2. Burkhart CG, Burkhart CN, Burkhart KM (1998) An assessment of topical and oral prescription and over-the-counter treatments for head lice. J Am Acad Dermatol 36:979–982CrossRefGoogle Scholar
  3. Carson D (1988) Pyrethrins combined with pipetonyl butoxide (RID) vs 1% permethrin (NIX) in the treatment of head lice. Am J Dis Child 142:768–769PubMedGoogle Scholar
  4. Haustein UF (1991) Pyrethrine und Pyrethroide (Permethrin) bei der Behandlung von Skabies und Pediculosis. Hautarzt 42:9–15PubMedGoogle Scholar
  5. Taplin D, Castillero PM, Spiegel J et al. (1982) Malathion for treatment of Pediculus humanus var capitis infestation. JAMA 247:3103–3105PubMedCrossRefGoogle Scholar
  6. Taplin D, Meinking T, Castillero P, Sanchez R (1986) Permethrin 1% creme rinse for the treatment of Pediculus humanus var capitis infestation. Pediat Dermatol 3:344–348CrossRefGoogle Scholar

■ Literatur

  1. Ash K, Lord J, Newman J et al. (1999) Hair removal using a long-pulsed alexandrite laser. Dermatol Clin 17:387–399PubMedCrossRefGoogle Scholar
  2. Bencini PL, Luci A, Galimberti M et al. (1999) Long-term epilation with long-pulsed neodymium: YAG laser. Dermatol Surg 25:175–178PubMedCrossRefGoogle Scholar
  3. Bjerring P, Zacharia H, Lybecker H et al. (1998) Evaluation of the free-running ruby laser for hair removal — a retrospective study. Acta Dermatol Venereol (Stockh) 78:48–51CrossRefGoogle Scholar
  4. Boss WK Jr, Usal H, Thompson RC et al. (1999) A comparison of the long-pulse and short-pulse alexandrite laser hair removal systems. Ann Plast Surg 42:381–384PubMedCrossRefGoogle Scholar
  5. Campos VB, Dierickx CC, Farinelli WA et al. (2000) Hair removal with an 800-nm pulsed diode laser. J Am Acad Dermatol 43:442–447PubMedCrossRefGoogle Scholar
  6. Connolly CS, Paolini L (1997) Study reveals successful removal of unwanted hair with LPIR laser. Cosmet Dermatol 10:38–40Google Scholar
  7. Dierickx CC, Grossman MC, Farinelli WA et al. (1997) Long-pulsed ruby laser hair removal. Lasers Surg Med 9(Suppl):167Google Scholar
  8. Dierickx CC, Grossman MC, Farinelli WA et al. (1998) Hair removal by a pulsed, infrared laser system. Lasers Surg Med 10(Suppl):198Google Scholar
  9. Dierickx CC, Grossman MC, Farinelli WA et al. (1998) Permanent hair removal by normal mode ruby laser. Arch Dermatol 134:837–842PubMedCrossRefGoogle Scholar
  10. Dierickx CC, Grossman MC, Farinelli WA et al. (1998) Comparison between a long-pulsed ruby laser and pulsed, infrared laser system for hair removal. Lasers Surg Med 10(Suppl):199Google Scholar
  11. Dierickx CC, Alora MB, Dover JS (1999) A clinical overview of hair removal using lasers and light sources. Dermatol Clin 17:357–366PubMedGoogle Scholar
  12. Duque V, Dierickx C, Lin D et al. (1998) Long-pulsed ruby laser for hair removal: comparisons between different spot size, temperatures, and interval between first and second treatment. Lasers Surg Med 10(Suppl):39Google Scholar
  13. Finkel B, Eliezri YD, Waldman A et al. (1997) Pulsed alexandrite laser technology for noninvasive hair removal. J Clin Laser Med Surg 15:225–229PubMedGoogle Scholar
  14. Garcia C, Alamoudi H, Nakib M et al. (2000) Alexandrite laser hair removal is safe for Fitzpatrick skin types IV-VI. Dermatol Surg 26:130–134PubMedCrossRefGoogle Scholar
  15. Gold MH, Bell MW, Foster TD et al. (1997) Long-term epilation using the Epilight broad band, intense pulsed light hair removal system. Dermatol Surg 23:909–913PubMedCrossRefGoogle Scholar
  16. Goldberg DJ, Littler CM, Wheeland RG (1997) Topical suspension-assisted Q-switched Nd:YAG laser hair removal. Dermatol Surg 23:741–745PubMedCrossRefGoogle Scholar
  17. Goldberg DJ, Samady JA (2000) Evaluation of a long-pulse Q-switched Nd:YAG laser for hair removal. Dermatol Surg 26:109–113PubMedCrossRefGoogle Scholar
  18. Görcü M, Asian G, Aköz T et al. (2000) Comparison of alexandrite laser and electrolysis for hair removal. Dermatol Surg 26:37–41CrossRefGoogle Scholar
  19. Grossman MC, Dierickx C, Farinelli W et al. (1996) Damage to hair follicles by normal-mode ruby laser irradiation. J Am Acad Dermatol 35:889–894PubMedCrossRefGoogle Scholar
  20. Gudat W, Hassoun G (1992) Epilation. Deutsche Dermatol 3:354–357Google Scholar
  21. Hobbs ER, Ratz JL, James B (1985) Electrosurgical epilation. Dermatol Clin 5:437–444Google Scholar
  22. Lask G, Elman M, Slatkine M et al. (1997) Laser-assisted hair removal by selective photothermolysis. Preliminary results. Dermatol Surg 23:737–739PubMedCrossRefGoogle Scholar
  23. Littler CM (1999) Hair removal using a Nd:Yag laser system. Dermatol Clin 17:401–430PubMedCrossRefGoogle Scholar
  24. Lynfield YL, Mac Williams P (1970) Shaving and hair growth. J Invest Dermatol 55:170–172PubMedCrossRefGoogle Scholar
  25. McDaniel DH, Lord J, Ash K et al. (1999) Laser hair removal. A review and report on the use of the long-pulsed alexandrite laser for hair reduction of the upper lip, leg, back, and bikini region. Dermatol Surg 25:425–430PubMedCrossRefGoogle Scholar
  26. Nanni CA, Alster TS (1997) Optimizing treatment parameters for hair removal using a topical carbon-based solution and 1064-nm Q-switched neodymium: YAG laser energy. Arch Dermatol 133: 1546–1549PubMedCrossRefGoogle Scholar
  27. Olsen EA (1999) Methods of hair removal. J Am Acad Dermatol 40:143–155PubMedCrossRefGoogle Scholar
  28. Richards RN, Meharg G (1995) Electrolysis: observation from 13 years and 140000 hours of experience. J Am Acad Dermatol 33:662–666PubMedCrossRefGoogle Scholar
  29. Ross EV, Ladin Z, Kreindel M et al. (1999) Theoretical considerations in laser hair removal. Dermatol Clin 17:333–355PubMedGoogle Scholar
  30. Schroeter CA, Raulin C, Thürlimann W et al. (1999) Hair removal in 40 hirsute women with an intense laser-like light source. Eur J Dermatol 9:374–379PubMedGoogle Scholar
  31. Scott MJ, Scott MJ III, Scott HM (1990) Epilation. Cutis 46:216–217PubMedGoogle Scholar
  32. Smith SR, Tse Y, Adit SK et al. (1998) Long-term results of hair photo-epilation. Lasers Surg Med (Suppl) 10:43Google Scholar
  33. Solomon MP (1998) Hair removal using the long-pulsed ruby laser. Ann Plast Surg 41:1–6PubMedCrossRefGoogle Scholar
  34. Tse Y (1999) Hair removal using a pulsed-intense light source. Dermatol Clin 17:373–385PubMedCrossRefGoogle Scholar
  35. Wagner RF (1990) Physical methods for the management of hirsutism. Cutis 45:19–26Google Scholar
  36. Williams R, Havoonjian H, Isagholian K et al. (1998) A clinical study of hair removal using the long-pulsed ruby laser. Dermatol Surg 24:837–842PubMedCrossRefGoogle Scholar
  37. Williams RM, Christian MM, Moy RL (1999) Hair removal using the long-pulsed ruby laser. Dermatol Clin17:367–372PubMedCrossRefGoogle Scholar

■ Literatur

  1. Board JA, Rosenberg SM, Smeltzer JS (1987) Spironolactone and estrogen-progestin therapy for hirsutism. South Med J 80:483–486PubMedCrossRefGoogle Scholar
  2. Camacho FM (1999) SAHA syndrome: female androgenetic alopecia and hirsutism. Exp Dermatol 8:304–305PubMedGoogle Scholar
  3. Carmina E, Lobo RA (1998) The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. Fertil Steril 69:1075–1079PubMedCrossRefGoogle Scholar
  4. Castello R, Tosi F, Perrone F et al. (1996) Outcome of long-term treatment with the 5-alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 66:734–740PubMedGoogle Scholar
  5. Chapman MG, Sowsett M, Dewhurst CJ et al. (1984) Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. Br J Obstet Gynecol 92:983–985Google Scholar
  6. Cusan L, Dupont A, Belanger A et al. (1990) Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 23:462–469PubMedCrossRefGoogle Scholar
  7. Erenus M, Yücelten D, Durmusoglu F, Gürbüz O (1997) Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 68:1000–1003PubMedCrossRefGoogle Scholar
  8. Givens JR, Andersen RN, Wiser WL et al. (1975) The effectiveness of two oral contraceptives in suppressing plasma androstendione, testosterone, LH and FSH and in stimulating plasma testosterone binding capacity in hirsute women. Am J Obstet Gynecol 124:333–339Google Scholar
  9. Hammerstein J, Cupceancu B (1969) Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wschr 94:829–834PubMedCrossRefGoogle Scholar
  10. Hammerstein J, Meckies J, Leo-Rossberg I et al. (1975) Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 6:827–836PubMedCrossRefGoogle Scholar
  11. Hauner H, Ditschuneit HH, Bals SB et al. (1988) Fat distribution, endocrine and metabolic profile in obese women with and without hirsutism. Metabolism 37:281–285PubMedCrossRefGoogle Scholar
  12. Kelestimur F, Sahin Y (1998) Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril 69:66–69PubMedCrossRefGoogle Scholar
  13. Labhart A (1990) 3000 Jahre Therapie des Hirsutismus. Zu W. Daums „Die Königin von Saba“. Schweiz Med Wochenschr 120:83–84PubMedGoogle Scholar
  14. Lobo RA (1986) “Idiopathic hirsutism” — fact or fiction. Sem Reprod Endocrinol 4:179–184CrossRefGoogle Scholar
  15. Lubowe I (1971) Achard-Thiers syndrome. Arch Dermatol 103:544–545PubMedCrossRefGoogle Scholar
  16. Moghetti P, Castello R, Negri C et al. (1995) Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor blockade. Fertil Steril 64:511–517PubMedGoogle Scholar
  17. Muderris II, Bayram F, Sahin Y et al. (1996) The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil Steril 66:220–222PubMedGoogle Scholar
  18. Muller SA (1973) Hirsutism: a review of the genetic and experimental aspects. J Invest Dermatol 60: 457–471PubMedCrossRefGoogle Scholar
  19. Pawlikowski M, Komorowski J (1983) Hyperostosis frontalis, galactorrhoea/hyperprolactinaemia, and Morgagni-Stewart-Morel syndrome. Lancet I:474CrossRefGoogle Scholar
  20. Tolino A, Petrone A, Sarnacchiario F et al. (1996) Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 66:61–65PubMedGoogle Scholar
  21. Venturoli S, Marescalchis O, Colombo FM et al. (1999) A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84: 1304–1310PubMedCrossRefGoogle Scholar
  22. Vexiau P, Bourdou P, Fiet J et al. (1995) 17β-estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate. Fertil Steril 63:508–515PubMedGoogle Scholar
  23. Wang IL, Morris RS, Chang L et al. (1995) A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 80:233–238CrossRefGoogle Scholar
  24. Watson RE, Bouknight R, Alguire PC (1995) Hirsutism: evaluation and management. J Gen Intern Med 10:283–292PubMedCrossRefGoogle Scholar

■ Literatur

  1. Malhorta B, Palmisano M, Schrode K et al. (2000) Percutaneous absorption, pharmacokinetics and dermal safety of eflornithine 15% cream in hirsute women (Poster). American Academy of Dermatology 58th Annual Meeting, San Francisco, März 10-15, 2000Google Scholar
  2. Schrode K, Huber F, Stszak J et al. (2000) Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair (Poster). American Academy of Dermatology 58th Annual Meeting, San Francisco, März 10-15, 2000Google Scholar

■ Literatur

  1. Ahmad W, Faiyaz ul Haque M, Brancolini V et al. (1998) Alopecia universalis associated with a mutation in the human hairless gene. Science 279:720–724PubMedCrossRefGoogle Scholar
  2. Cotsarellis G, Sun TT, Lavker RM (1990) Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle and skin carcinogenesis. Cell 61:1329–1337CrossRefGoogle Scholar
  3. Grossman MC, Wimberly J, Dwyer P et al. (1995) PDT for hirsutism. Lasers Surg Med 7(Suppl):44Google Scholar
  4. Grossman MC (1997) What is new in cutaneous laser research. Dermatol Clin 15:1–8PubMedGoogle Scholar
  5. Li L, Hoffman RM (1995) The feasibility of targeted selective gene therapy of the hair follicle. Nature Med 1:705–706PubMedCrossRefGoogle Scholar
  6. Protopapa EE, Gaissert H, Xenckis A et al. (1999) The effect of proteolytic enzymes on hair follicles of transgenic mice expressing the lac Z-protein in cells of the bulge region. J Eur Acad Dermatol 13:28–35CrossRefGoogle Scholar

■ Literatur

  1. Casagrande F, Lehner H, Lienhard B, Simmen A (1998) Haare — Cheveux — Capelli. Handbuch für den Coiffeurberuf. Schweizerische Coiffeurfachlehrer-VereinigungGoogle Scholar
  2. Dauer H-G (2000) Haarwebesystem (“hair weaving”). In: Plettenberg A, Meigel WN, Moll I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend. Aktueller Stand von Klinik und Forschung. Springer, Berlin, S 725–730Google Scholar
  3. Farm G (1998) Contact allergy to colophony. Clinical and experimental studies with emphasis on clinical relevance. Acta Dermatol Venereol Suppl (Stockh) 201:1–42Google Scholar
  4. Rayner VL (1994) Camouflage cosmetics. In: Baran R, Maibach HI (eds) Cosmetic Dermatology. Williams & Wilkins, Baltimore, pp 205–226Google Scholar
  5. Unger WP (1977) Alternatives in hair replacement. Cutis 19:623–628PubMedGoogle Scholar
  6. Van der Velden EM, Drost BH, Ijsselmuiden OE et al. (1998) Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol 37: 617–621PubMedCrossRefGoogle Scholar

■ Literatur

  1. Friederich HC, Georg ML (1990) Operative Behandlung der Alopezie. Akt Dermatol 16:7–16Google Scholar
  2. Hanke CW, Bergfeld WF (1979) Fiber implantation for pattern baldness. JAMA 241:146–148PubMedCrossRefGoogle Scholar
  3. Hanke CW, Norins AL, Pantzer JG, Bennett J (1981) Hair implant complications. JAMA 245:1344–1345PubMedCrossRefGoogle Scholar
  4. Lepaw MI (1979) Complications of implantation of synthetic fibers into scalp for “hair” replacement. J Dermatol Surg Oncol 5:201–204PubMedGoogle Scholar
  5. Limmer Bl (1995) Elliptical donor stereoscopically assisted micrografting as an approach to further refinement in hair transplantation. J Dermatol Surg Oncol 20:789–793Google Scholar
  6. Lukas M, Halsner U (1990) Haartransplantationen bei Frauen — neue Perspektiven der Mini-Graft-Technik. Akt Dermatol 16:17–20Google Scholar
  7. Marritt M, Konior RJ (1994) Patient selection, candidacy, and treatment plan for hair replacement surgery. Facial Plastic Surg Clin North Am 2:111–131Google Scholar
  8. Mühlbaur W (1970) Haartransplantationen bei post-traumatischer Alopezie. Münch med Wschr 37: 1655–1659Google Scholar
  9. Nelson BR, Stough DB, Stough DB, Johnson T (1991) Hair transplantation in advanced male pattern alopecia. The role of incicional slit grafting. J Dermatol Surg Oncol 17:567–573PubMedGoogle Scholar
  10. Norwood OT (1984) Transplanting temporal points, sideburns and feminine hairline. J Dermatol Surg Oncol 10:958–961PubMedGoogle Scholar
  11. Norwood OT (1992) Patient selection, hair transplant design, and hairstyle. J Dermatol Surg Oncol 18: 386–394PubMedGoogle Scholar
  12. Peluso AM, Fanti PA, Monti M et al. (1992) Cutaneous complications of artificial hair implantation: a pathological study. Dermatology 184:129–132PubMedCrossRefGoogle Scholar
  13. Rassman WR, Carson S (1995) Micrografting in extensive quantities. Dermatol Surg 21:306–311PubMedCrossRefGoogle Scholar
  14. Stough DB, Miner JE (1997) Male pattern alopecia. Surgical options. Dermatol Clin 15:609–622PubMedCrossRefGoogle Scholar
  15. Stough DW, Potter TS (1997) Philosophy and technique in hair restoration surgery. Curr Probi Dermatol 9:113–136CrossRefGoogle Scholar
  16. Swinehart JM, Griffin EI (1991) Slit grafting: the use of serrated island grafts in male and female-pattern alopecia. J Dermatol Surg Oncol 17:243–253PubMedGoogle Scholar
  17. Uebel CO (1991) Micrografts and minigrafts: a new approach for baldness surgery. Ann Plast Surg 27:476–487PubMedCrossRefGoogle Scholar
  18. Unger MG (1992) Scalp reduction. Clin Dermatol 10:345–355PubMedCrossRefGoogle Scholar
  19. Unger WP, David LM (1994) Laser hair transplantation. J Dermatol Surg Oncol 20:515–521PubMedGoogle Scholar
  20. Unger WP (1996) What’s new in hair replacement surgery? Dermatol Clin 14:783–802PubMedCrossRefGoogle Scholar

■ Literatur

  1. Bleuler E (1975) Das autistisch-undisziplinierte Denken in der Medizin und seine Überwindung. Springer, BerlinGoogle Scholar
  2. Klobusch J, Mössier K, Rabe T, Runnebaum B (1990) Neue Ansätze in Diagnostik und Therapie der Alopezie in der Gynäkologie. Ther Umsch 47:985–990PubMedGoogle Scholar
  3. Lange S (1999) Statistisch signifikant — auch relevant für den Patienten? Med Klin 94(Suppl):22–24CrossRefGoogle Scholar
  4. Lassus A, Eskelinen E (1992) A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenetic alopecia in young males. J Int Med Res 20:445–453PubMedGoogle Scholar
  5. Loussouarn G, Courtois M, Horuseau C et al. (1997) A new approach to the prevention and cosmetic treatment of alopecia. Aminexil. BEDC 5:1–5Google Scholar
  6. Maddin WS, Bell PW, James JHM (1990) The biological effects of a pulsed electrostatic field with specific reference to hair. Int J Dermatol 29:446–450PubMedCrossRefGoogle Scholar
  7. Maddin S (1992) Electrotrichogenesis: further evidence of efficacy and safety on extended use. Int J Dermatol 31:878–880PubMedCrossRefGoogle Scholar
  8. Mössier K (1991) Thymu-Skin: Neuer Therapieansatz bei der Behandlung der Alopecia androgenetica und der Alopecia areata. Deutsch Dermatol 39: 3–10Google Scholar
  9. Sawaya ME, Shapiro J (2000) Alopecia: unapproved treatments or indications. Clin Dermatol 18:177–186PubMedCrossRefGoogle Scholar

■ Literatur

  1. Ahmad W, Faiyaz ul Haque M, Brancolini V et al. (1998) Alopecia universalis associated with a mutation in the human hairless gene. Science 279:720–724PubMedCrossRefGoogle Scholar
  2. Augustin M (2001) Erfassung von Lebensqualität in dermatologischen Studien. Leitlinie der Subkommission „Pharmako-Ökonomie und Lebensqualität“. Hautarzt 52:697–700Google Scholar
  3. Badiavas EV, Falanga V (2001) Gene therapy. J Dermatol 28:175–192PubMedGoogle Scholar
  4. Braun-Falco M, Hallek M (1998) Hautgentherapie — Perspektiven des Gentransfers in Keratinozyten. Hautarzt 49:536–544PubMedCrossRefGoogle Scholar
  5. Chan EF, Gat U, McNiff JM, Fuchs E (1999) A common human skin tumour is caused by activating mutations in beta-catenin. Nat Gene 21:410–413CrossRefGoogle Scholar
  6. Cotsarelis G, Sun TT, Lavker RM (1990) Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle and skin carcinogenesis. Cell 61:1329–1337PubMedCrossRefGoogle Scholar
  7. Davis ST, Benson BG, Bramson HN et al. (2001) Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291:134–137PubMedCrossRefGoogle Scholar
  8. De Luca M, Pellegrini G (1997) The importance of epidermal stem cells in keratinocyte-mediated gene therapy. Gene Ther 4:381–383PubMedCrossRefGoogle Scholar
  9. Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI) — a simple practical measure for routine clinical use. Clin Expe Dermatol 19:210–216CrossRefGoogle Scholar
  10. Fischer TW, Schmidt S, Strauss B, Eisner P (2001) Hairdex. Ein Instrument zur Untersuchung der krankheitsbezogenen Lebensqualität bei Patienten mit Haarerkrankungen. Hautarzt 52:219–227PubMedCrossRefGoogle Scholar
  11. Fuchs E (1998-99) Beauty is skin deep: the fascinating biology of the epidermis and its appendages. Harvey Lect 94:47–77PubMedGoogle Scholar
  12. Fuchs E, Merrill BJ, Jamora C, DasGupta R (2001) At the roots of a never-ending cycle. Dev Cell 1:13–25PubMedCrossRefGoogle Scholar
  13. Gat U, DasGupta R, Degenstein L, Fuchs E (1998) De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 95:605–614PubMedCrossRefGoogle Scholar
  14. Hoffman RM (1998) Topical liposome targeting of dyes, melanins, genes, and proteins selectively to hair follicles. J Drug Target 5:67–74PubMedCrossRefGoogle Scholar
  15. Hoffmann R (2001) TrichoScan: combining epiluminiscence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol 11:362–368PubMedGoogle Scholar
  16. Jahoda CAB, Oliver RF, Reynolds AJ et al. (2001) Transspecies hair growth induction by human hair follicle dermal papillae. Exp Dermatol 10:229–237PubMedCrossRefGoogle Scholar
  17. Li L, Hoffman RM (1995) The feasibility of targeted selective gene therapy of the hair follicle. Nature Med 1:705–706PubMedCrossRefGoogle Scholar
  18. Lu B, Federoff HJ, Wang Y et al. (1997) Topical application of viral vectors for epidermal gene transfer. J Invest Dermatol 108:803–808PubMedCrossRefGoogle Scholar
  19. McKay IA, Winyard P, Leigh IM, Bustin SA (1994) Nuclear transcription factors: potential targets for new modes of intervention in skin disease. Br J Dermatol 131:591–597PubMedCrossRefGoogle Scholar
  20. Millar SE (2002) Molecular mechanisms regulating hair follicle development. J Invest Dermatol 118:216–225PubMedCrossRefGoogle Scholar
  21. Paus R, Menrad A, Czarnetski B (1995) Nekrobiologie der Haut: Apoptose. Hautarzt 46:285–303PubMedGoogle Scholar
  22. Paus R, Christoph T, Müller-Röver S (1999) Immunology of the hair follicle: a short journey into terra incognita. Invest Dermatol Symp Proc 4:226–234CrossRefGoogle Scholar
  23. Paus R, Müller-Röver S, Botchkarev VA (1999) Chrono-biology of the hair follicle: hunting the “hair cycle clock”. Invest Dermatol Symp Proc 4:338–345CrossRefGoogle Scholar
  24. Reynolds AJ, Lawrence C, Cserhalmi-Friedman PB, Christiano AM, Jahoda CA (1999) Trans-gender induction of hair follicles. Human follicle cells can be induced to grow in an incompatible host of the other sex. Nature 402:33–34PubMedCrossRefGoogle Scholar
  25. Ritzmann P (2000) Medizinische Informationen auf dem Internet. Schweiz Rundsch Med Prax 89:706–710Google Scholar
  26. Shum D, Martinka M, Bernardo O et al. (2001) Computer-assisted histomorphometric evaluation of scalp biopsies (abstract 257). J Invest Dermatol 117:432Google Scholar
  27. Trüeb RM (1998) Von der Hippokratischen Glatze zum “Gen-Shampoo”: Fortschritte der Trichologie im Jahrtausendwechsel. Akt Dermatol 24:101–107Google Scholar
  28. Trüeb RM (1998) Mutation des menschlichen hairless-Gens bei Atrichia universalis. Hautarzt 49:678–689CrossRefGoogle Scholar
  29. Trüeb RM (2000) Kampf der Glatze: Von der Magie zur Therapie. Neue Zürcher Zeitung 102:73Google Scholar
  30. Trüeb RM, Swiss Trichology Study Group (2001) The value of hair cosmetics and pharmaceuticals. Dermatology 202:275–282PubMedCrossRefGoogle Scholar
  31. Trüeb RM (2001) Das Haar im Spiegel der Geschichte. In: Burg G, Geiges ML (Hrsg) Die Haut, in der wir leben. Zu Markt getragen und zur Schau gestellt. Rüffer & Rub, Zürich, S 160–166Google Scholar
  32. van Genderen C, Okamura RM, Farinas I et al. (1994) Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 15: 2691–2703CrossRefGoogle Scholar
  33. Wagner RW (1994) Gene inhibition using antisense oligonucleotides. Nature 372:333–335PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ralph M. Trüeb
    • 1
  1. 1.Dermatologische KlinikUniversitätsSpital ZürichSwitzerland

Personalised recommendations